Home › Compound Library › Velpatasvir

Velpatasvir

Antiviralprescriptionoral · inferred

Pan-genotypic HCV NS5A inhibitor; component of Epclusa (sofosbuvir/velpatasvir). Not typically used as monotherapy.

Projected serum levels — 100 mg, once daily

Velpatasvir
Velpatasvir modeled serum levels, 100 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
Velpatasvir modeled serum levels with a loading dose of 130 mg, then 100 mg once daily The first dose is larger so levels approach steady state faster. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 100 mg once daily (oral).

Loading schedule: 130 mg on day 1, then 100 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 54.7 mg, trough ≈ 15.1 mg body load. Population-based estimate over 15 days for a 100 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiviral
Route modeled
Oral
Model confidence
inferred
Half-life
15 h
Common dose
100 mg
Suggested maximum
100 mg/day
Reference dose range
50–100 mg (single dose)
Suggested cadence
once daily
Validated against
100 mg oral — Cmax 0.31 mg/L at 3 h

Documented interactions

  • danger
    Carbamazepine (Tegretol) + Velpatasvir CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Velpatasvir AUC by ~0.33x

  • danger
    Efavirenz (Sustiva) + Velpatasvir CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Velpatasvir AUC by ~0.22x

  • danger
    Levothyroxine (Synthroid) + Velpatasvir Protein binding

    Velpatasvir may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration changes…

  • danger
    Phenobarbital + Velpatasvir CYP induction

    Phenobarbital inducer of CYP3A4 predicted to change Velpatasvir AUC by ~0.50x

  • danger
    Phenytoin (Dilantin) + Velpatasvir CYP induction

    Phenytoin (Dilantin) inducer of CYP3A4 predicted to change Velpatasvir AUC by ~0.50x

  • danger
    Rifampin + Velpatasvir CYP induction

    Rifampin inducer of CYP3A4 predicted to change Velpatasvir AUC by ~0.22x

Serum checks 234 modeled interaction pairings for velpatasvir across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical Pharmacokinetics and Drug-Drug Interactions of Sofosbuvir/Velpatasvir Mogalian E et al. · Clinical Pharmacokinetics, 2017 DOI

    Characterizes velpatasvir absorption, protein binding, CYP3A4 and P-gp interactions, and fixed-dose combination PK with sofosbuvir.

  2. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Feld JJ et al. · New England Journal of Medicine, 2015 DOI

    ASTRAL-1 trial demonstrating 99% SVR with 12-week sof/vel across HCV genotypes.

2 published studies referenced in the app, each with a plain-language summary.